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It is essential to bear in mind that the
native conformation of human proteins
is stabilized by intra-molecular disulfide
(S–S) bonds between a single or multiple
polypeptide chains. The formation of S–S
bonds is catalyzed by protein disulfide iso-
merase (PDI) (1), the activation of which
is associated with a number of human dis-
eases, such as myocardial infarction, stroke,
and cancer. Unless proper chaperone pro-
teins are available the accidental cleavage
of S–S linkages will result in the unfolding
and scrambled refolding of the polypeptide
chains thus producing non-native species
present in many degenerative diseases (2–
5). This process is the most common pro-
tein post-translational modification that,
for example, in a protein with 9 disulfide
bridges can theoretically form 34,459,425
different disulfide-bonded isomers, only
one with a correct protein function. How-
ever, the most damaging consequence of
such a modification is the formation of
protein aggregates known as “inclusion
bodies” that are resistant to the enzymatic
degradation (6). This unusual phenome-
non is the result of the formation of inter-
molecular hydrophobic bonds, which in
contrast to peptide links are not susceptible
to the catalytic hydrolysis. It is known that
the strongest and practically irreversible
protein interactions involve hydrophobic
bonds, which in native proteins are buried
inside their tertiary structure (7).
One of the blood proteins rich in disul-
fides is fibrinogen (Fbg), the physiologic
function of which is to provide hemo-
static fibrin plug formed by the action
of enzyme thrombin. This insoluble poly-
mer, when formed at the site of vessel
wall injury, is eventually removed by the
action of fibrinolytic enzyme system, to
give space for the growth of a connec-
tive tissue and to ensure proper wound
healing. To speed up the process of fibrin
elimination from the coronary or cerebral
circulations, several thrombolytic thera-
pies have been devised with the use of a
variety of fibrinolytic agents. It is, how-
ever, well recognized in clinical practice
that such therapies are effective only when
installed 3–5 h after the onset of throm-
bosis (8). This enigma is now resolved
by the discovery of the alternative path-
way of blood coagulation induced with
iron (9). Thus, in contrast to thrombin-
generated fibrin the iron-induced parafib-
rin is totally resistant to the fibrinolytic
degradation. This is due to the fact that
parafibrin has different a tertiary structure
than fibrin formed with thrombin. We have
showed that such a dramatic modification
of fibrin structure is due to the unfolding
and scrambled refolding of Fbg disulfide-
linked subunits leading to the exposure of
hydrophobic epitopes in their polypeptide
chains (9). The cleavage of disulfide bonds
is induced by biologically highly reactive
hydroxyl radicals (HO·) formed in the reac-
tion between trivalent iron with hydroxyl
groups of water according to the following
formula:
Fe3+ +HO− → Fe2+ +HO•.
As the consequence of the hydroxyl rad-
ical interaction with Fbg a huge protease
resistant polymer is formed that remains
in the circulation for a long time, result-
ing in a state of chronic inflammation due
to the attraction of cytotoxic albeit inef-
fective T cells. The accumulating evidence
indicates that there is a correlation between
increased blood concentration of unbound
iron and the incidence of cancer in humans
(10–13), and that its reduction may pre-
vent cancer morbidity and mortality (14).
It should be noted that it is only the triva-
lent iron (Fe3+), and not divalent (Fe2+),
which participate in the generation of
hydroxyl radicals and subsequent forma-
tion of insoluble parafibrin from soluble
plasma Fbg. However, when hemoglobin
is released from the hemolyzed erythro-
cytes, the divalent ferrous ions are enzy-
matically converted to ferric ions. Thus,
any pathologic condition in which erythro-
cyte membranes are damaged, e.g., in infec-
tions and/or after exposure to environmen-
tal toxins, may contribute to the excessive
body storage of trivalent iron. It should be
borne in mind that this form of iron accu-
mulates with age due to the fact that there is
no mechanism for its physiologic elimina-
tion, and may therefore, explain association
of cancer with aging.
The unsuccessful attempts at removing
parafibrin by the human body defense sys-
tems were recently suggested to contribute
to Alzheimer’s disease (15) as well as to the
cardiovascular disease (16). These diseases
and other degenerative disorders have been
known to respond well to dietary mod-
ifications, particularly to those associated
with the so-called Mediterranean diet (17),
which is rich in natural amphiphilic sub-
stances such as polyphenols and flavones.
Relevant to the concept presented in this
article is the fact that protein unfold-
ing can be inhibited by natural products
present in tea, fruits, berries, and certain
grains, the consumption of which is known
to lower the incidence of degenerative
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FIGURE 1 | Schematic presentation of a putative mechanism of the anticancer effect of
amphiphilic substances that displace parafibrin from surface of the cancer cell membrane.
diseases (18). In addition, there is another
important component of human diet, sele-
nium, which is known to prevent various
forms of cancer (19–23). Hence, sodium
selenite, but not selenate, reacts with free
sulfhydryl groups of proteins, thus prevent-
ing reductive cleavage of disulfide bonds
followed by protein unfolding and abnor-
mal refolding (24, 25).
It is proposed in this paper that the bar-
rier formed around tumor cells composed
of proteolytically resistant parafibrin can
be removed by a non-enzymatic mecha-
nism based on the interaction of hydropho-
bic and hydrophilic groups (Figure 1).
Numerous natural substances, particu-
larly those of amphiphilic nature such as
polyphenols, when ingested with diet in
sufficient quantities can prevent and/or
reverse cancer formation and metastases
(26–33). These findings may explain ben-
eficial effects of the Mediterranean diet
known to be associated with lower inci-
dence of cancer and other degenerative
diseases (34).
According to the mechanism shown
in Figure 1 amphiphilic substances taken
up with food interfere with and/or dis-
place the hydrophobic coat on cancer cells
membranes thus exposing neoantigens and
making tumors vulnerable to the natural
killer cells attack and lysis.
In conclusion, the concept delineated
in this article supports the original notion
expressed by Basmadijan et al. (35)
according to which natural products have
a potential to be developed into novel
anticancer medicines.
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